CytoSorbents Corporation (CTSO)

[biotech48]

No, we do not all agree that the rise from 6 to 7 was driven by "insider driven hike". That is ridiculous. We were and are undervalued to begin with. Then there were also stellar Q2 and Q3 earnings during that period along with news of introducing the ECMO Kit, the awarding of a phase 2 SBIR $1m grant to treat severe hyperkalemia, being recognized as being one of the fastest growing tech companies by Deloitte, an update on the start of the PACIFICA trial, using CytoSorb to treat severe acute pancreatitis, persistent rumors for future cancer applications,Aferetica and CytoSorbents Partnering to Enhance the Success of Solid Organ Transplantation. All of this and more has occurred during the rise from $5.40 to $7. It is a wonder that it hasn't been driven more higher.